U.S. patent application number 11/892283 was filed with the patent office on 2009-09-10 for early detection of flaviviruses using the ns1 glycoprotein.
This patent application is currently assigned to Institut Pasteur. Invention is credited to Sophie Alcon, Philippe Despres, Vincent Deubel, Marie Flamand, Francoise Megret, Antoine Talarmin.
Application Number | 20090226478 11/892283 |
Document ID | / |
Family ID | 26234982 |
Filed Date | 2009-09-10 |
United States Patent
Application |
20090226478 |
Kind Code |
A1 |
Flamand; Marie ; et
al. |
September 10, 2009 |
Early detection of flaviviruses using the NS1 glycoprotein
Abstract
The invention concerns a method for early detection of a
flavivirus-induced infection, comprising the detection of the
flavivirus non-structural glycoprotein NS1 in a biological sample
during the clinical phase of the infection, by an immunological
method using at least two identical or different antibodies, the
first antibody consisting of polyclonal or monoclonal antibodies
pre-selected for their high affinity for said NS1 protein hexameric
in shape.
Inventors: |
Flamand; Marie; (Paris,
FR) ; Megret; Francoise; (Paris, FR) ; Alcon;
Sophie; (Livry-Gargan, FR) ; Talarmin; Antoine;
(Paris, FR) ; Despres; Philippe;
(Garenne-Colombes, FR) ; Deubel; Vincent; (Vanves,
FR) |
Correspondence
Address: |
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER;LLP
901 NEW YORK AVENUE, NW
WASHINGTON
DC
20001-4413
US
|
Assignee: |
Institut Pasteur
|
Family ID: |
26234982 |
Appl. No.: |
11/892283 |
Filed: |
August 21, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11017048 |
Dec 21, 2004 |
7282341 |
|
|
11892283 |
|
|
|
|
09980839 |
Jun 21, 2002 |
6870032 |
|
|
11017048 |
|
|
|
|
Current U.S.
Class: |
424/186.1 ;
435/69.1 |
Current CPC
Class: |
Y10S 435/975 20130101;
C07K 16/1081 20130101; A61K 2039/505 20130101; A61K 39/12 20130101;
A61K 39/00 20130101; G01N 2333/18 20130101; A61P 37/04 20180101;
C12N 2770/24134 20130101; A61P 43/00 20180101; C12N 2770/24122
20130101; Y02A 50/30 20180101; C07K 14/005 20130101; G01N 2469/10
20130101; A61P 31/14 20180101; G01N 33/56983 20130101 |
Class at
Publication: |
424/186.1 ;
435/69.1 |
International
Class: |
A61K 39/12 20060101
A61K039/12; C12P 21/02 20060101 C12P021/02 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 9, 1999 |
FR |
FR 99 07290 |
Jun 10, 1999 |
FR |
FR 99 07361 |
Claims
1-20. (canceled)
21. A method for purifying an NS1 protein of a flavivirus, wherein
the NS1 protein is in hexameric form, from a culture supernatant
either of infected mammalian cells or of mammalian cells
transfected with a recombined plasmid, comprising: (A) expressing
the NS1 protein or a fragment of the NS1 protein from an NS1 gene
or a fragment of the flaviviral genome, wherein the fragments are
capable of expressing the NS1 protein prior to the purification of
the NS1 protein; (B) treating the NS1 protein with a precipitating
agent; (C) centrifuging the treated NS1 protein; and, (D)
separating a soluble form of the NS1 protein from a
microparticulate form of NS1 protein.
22. The method for purifying NS1 protein as claimed in claim 27,
wherein the flavivirus is a dengue virus.
23. The method for purifying NS1 protein as claimed in claim 28,
wherein the flavivirus is dengue virus serotype 1.
24. An immunogenic composition, comprising as the active principle,
an NS1 protein of a flavivirus, wherein the NS1 protein is in
hexameric form, optionally associated with other proteins, and at
least one pharmaceutical vehicle.
25. The immunogenic composition as claimed in claim 30, wherein the
composition further comprises at least one mixture of NS1 proteins
in hexameric form of a dengue virus serotype.
26. A method for preparing an immunogenic composition capable of
inducing the production of antibodies in vivo comprising combining
an NS1 protein in hexameric form, or an NS1 protein expressed from
a system for the expression of NS1 protein in hexameric form, with
at least one pharmaceutical vehicle.
27. A method for manufacturing a medicinal product capable of
inducing passive immunization comprising producing at least one
monoclonal anti-NS1 antibody having a high affinity for NS1 protein
in hexameric form, purifying the monoclonal antibody, and modifying
the monoclonal antibody by selecting for Fab fragments or
humanizing the monoclonal antibody, wherein the hexameric form is
nondegraded.
28. An immunogenic composition, comprising an active principle and
a pharmaceutical vehicle, wherein the active principle is either a
polynucleotide capable of expressing all or part of an NS1 protein
of a dengue virus of any serotype, or the active principle is an
expression system comprising at least one promoter capable of
expressing, in a host into which it is injected, a DNA encoding an
NS1 protein of a dengue virus of any serotype.
29. A method for expressing a polynucleotide encoding an NS1
protein of a dengue virus, comprising associating a polynucleotide
of SEQ ID No. 1 with a promoter for said polynucleotide, and
expressing the polynucleotide in a eukaryotic cell.
Description
[0001] The present invention relates to a method for the early
detection of flaviviruses, in particular of the dengue virus, and
to the application thereof.
[0002] Dengue is an acute febrile tropical disease and the virus
which causes it is an arbovirus which is transmitted by mosquitoes.
The vectors of the disease are mosquitoes of the Aedes genus, in
particular Aedes aegypti, which most commonly leave their larvae in
domestic and peridomestic areas. The responsible virus, isolated in
1951, has been classified into four different antigenic types
(DEN1, DEN2, DEN3 and DEN4). It belongs to the Flaviviridae family,
genus flavivirus.
[0003] More than two billion inhabitants live in endemic regions
and the number of individuals infected by the virus is thought to
be more than 100 million per year. Dengue is in particular
responsible for 500 000 hospitalizations and for several tens of
thousands of deaths annually, mostly children.
[0004] After an incubation of five to eight days, the clinical
signs generally begin suddenly and consist of the appearance of
undifferentiated fever (DF dengue fever) accompanied by severe
headaches, lumbago, muscle and joint pain and also shivering. From
the third to the fifth day of the febrile phase, a congestive
maculopapular rash may appear for three to four days (conventional
dengue).
[0005] In its severe form, the infection may result in the
appearance of a hemorrhagic syndrome (DHF or dengue hemorrhagic
fever), characterized by increased vascular permeability and
deregulation of hemostasis. Although, in the majority of cases, the
disease generally evolves favorably within a week, it may turn out
to be fatal in the event of hypovolemic shock (DSS or dengue shock
syndrome). These complications may be due to the presence of
preexisting immunity, acquired in particular during a primary
infection with a heterologous dengue virus (different serotype).
Specifically, two different types of serological response are
identified in individuals infected with dengue: individuals who
have never suffered a flavivirus infection and have not been
vaccinated against another flavivirus (yellow fever virus, Japanese
encephalitis virus for example) will exhibit a primary response,
characterized by a slow appearance of antibodies specific for the
virus responsible for the infection; individuals who have already
suffered a flavivirus infection (other dengue serotype for example)
or have been vaccinated against another flavivirus will exhibit a
secondary response, characterized by the rapid appearance of
antibodies.
[0006] The infectious agent is the dengue virus which belongs to
the Flaviviridae family, to which the yellow fever virus and the
Japanese encephalitis virus also belong (T. P. Monath et al.,
(1996) Flaviviruses in B. N. Fields, D. M. Knipe, P. M. Howly et
al. (eds.) "Fields Virology" Philadelphia: Lippincott Raven Press
Publishers). These viruses have a single-strand RNA with positive
polarity which comprises 11 000 nucleotides and which encodes a
polyprotein of approximately 3400 amino acids. It is separated into
three structural proteins and seven nonstructural proteins NS1,
NS2A, NS2B, NS3, NS4A, NS4B and NS5, during co-translational and
post-translational cleavage by viral and cellular proteases. The
NS1 nonstructural protein was identified for the first time in 1970
by P. K. Russel et al. (J. Immunol., (1970), 105, 838-845) and
characterized in 1985 by G. W. Smith et al. (J. Gen Virol., (1985),
66, 559-571). This glycoprotein, which is highly conserved in the
flavivirus genus (T. P. Monath already mentioned), in particular in
the four dengue virus serotypes, exists in an intracellular form
and in an extracellular form. The intracellular form is thought to
be involved in the early phases of replication of the virus (Hall
R. A. et al., J. Virol. (1999), 73, 10272-10280; Rice C. M. et al.,
J. Virol., (1997), 71, 291-298; Rice C. M. et al., J. Virol.,
(1996), 222, 159-168; Rice C. M. et al., J. Virol., (1997), 71,
9608-9617). Before being transported to the plasma membrane, the
NS1 protein undergoes dimerization. In mammalian cells, but not in
insect cells, a portion of the NS1 protein is released into the
extracellular medium, either primarily in the form of a soluble
protein, or secondarily in a microparticulate form. When it is in a
soluble form, the protein exists in the form of an oligomer, in
particular of a pentamer or of a hexamer (Crooks A. J. et al. J.
Chrom. (1990), 502, 59-68 and J. Gen. Virol. (1994), 75,
3453-3460). At the current time, the biological function of the NS1
protein is unknown.
[0007] Several studies suggest that the NS1 protein is
immunodominant in nature in the protective immune response against
flavivirus infections. Experiments carried out with a certain
number of flaviviruses, such as the yellow fever, dengue, Japanese
encephalitis and tick-borne encephalitis viruses, have shown
partial or total protection against a lethal dose of homologous
virus in animals vaccinated using the subunit NS1 protein or the
NIS1 protein produced by virus vectors, of the vaccinia or
adenovirus type (Schlesinger et al., J. Virol (1986), 60,
1153-1155; J. Gen. Virol., (1987), 68, 853-857; Falgout et al. J.
Virol., (1990), 64, 4356-4363; Jacobs et al. J. Virol., (1992), 66,
2086-2095; Hall et al. J. Gen. Virol., (1996), 77, 1287-1294;
Konishi et al., Virology, (1991), 185, 401-410). Passive
immunization of mice with monoclonal anti-NS1 antibodies has also
made it possible to obtain a certain degree of protection
(Schlesinger et al., J. Immunol. (1985), 135, 2805-2809; Gould et
al. J. Gen. Virol., (1986), 67, 591-595; Henchal et al., J. Gen.
Virol., (1988), 69, 2101-2107). The role of anti-NS1 antibodies in
the protection is not entirely known. It may be that the NS1
proteins at the surface of infected cells are recognized by
complement-fixing antibodies, leading to lysis of the infected
cells (Schlesinger et. al., Virology, (1993), 192, 132-141).
[0008] No specific treatment exists and the care given to the
patient is uniquely symptomatic. In the case of conventional
dengue, the treatment is based on the administration of analgesics
and antipyretics. In the case of DHF, the treatment consists of an
infusion to compensate for the plasma leakage, combined with
correction of hydroelectric problems and reinitiation of
diuresis.
[0009] There is no commercially available vaccine against the
dengue virus. On the other hand, protection assays with attenuated
strains of the 4 dengue virus serotypes have been carried out by N.
Bhamarapravati et al. (Dengue and Dengue haemorrhagic fever (1997),
367-377), with unsatisfactory results. Prevention is therefore
based solely on combating the vector. This combat combines larval
destruction and "adulticide" spraying.
[0010] In the absence of a vaccine, it is necessary to monitor
epidemics and to prevent the above-mentioned complications; to do
this, active monitoring programs have in particular been set up by
the World Health Organization, and essentially comprise the
monitoring of cases of fever and of vector insects, and the
serological and virological screening of individuals having a fever
and suspected of being infected with the dengue virus.
[0011] The etiology of dengue is sometimes tricky to affirm when a
patient exhibits a dengue-like undifferentiated febrile syndrome,
the cause of which may be another arbovirus, viruses which cause
eruptive fevers such as the flu, or nonviral pathogens which are
agents of diseases such as leptospirosis and even malaria. Only a
laboratory test can provide the diagnosis.
[0012] At the current time, several tests exist for diagnosing
dengue. However, in order to obtain an interpretable result, it is
necessary to combine several methods: [0013] isolation of the
virus, by conventional virology techniques, in particular by
infection of cell cultures or propagation in the brain of young
mice or amplification by inoculation into mosquitoes, and
examination, for example, by immunofluorescence. These methods have
the drawback of being difficult to carry out and of depending on
the sample being taken early and on good conditions of
conservation; in addition, the first results cannot be obtained in
less than a week; in order to overcome these drawbacks, use may be
made of an RT/PCR test (V. Deubel, L'eurobiologiste (1997), volume
XXXI, 37-155); however, this means is not always reliable and
cannot be used routinely in the countries to which the dengue virus
relates, for reasons of cost and equipment; [0014] serological
tests; the earliest serological diagnosis consists in searching for
IgMs specific for viral antigens using the MAC-ELISA
(immunoglobulin M Antibody Capture Enzyme-Linked-ImmunoSorbent
Assay) technique. Detection of these IgMs several days after the
beginning of the symptoms makes it possible to establish a
diagnosis of probability of infection with a flavivirus. Antibodies
of the IgG type appear later than antibodies of the IgM type. In
all cases, the search for antibodies requires two samples: one at
the beginning of the clinical signs, the other 10 to 28 days later,
so as to demonstrate serological conversion via an inhibition of
hemagglutination reaction (IHA) or by ELISA.
[0015] Simple and inexpensive immunological tests have also been
proposed, which can be used in the countries at risk and which use,
as a specific immunological reagent, peptides derived from the NS1
nonstructural protein characteristic of flaviviruses. Thus, U.S.
Pat. No. 5,824,506 describes a method using peptides derived from
the NS1 nonstructural protein, which makes it possible to detect
the antibodies induced by the presence of the dengue virus;
however, the peptides selected essentially recognize samples
obtained from convalescent individuals and also recognize patients
infected for the second time better than those infected for the
first time; these disappointing results may be explained by the
fact that the peptides used are not representative of the antigenic
characteristics of the native protein and therefore lead to poor
recognition of the antibodies being sought.
[0016] In all cases, only late confirmation of an infection with a
flavivirus may be given.
[0017] A report from the Sir Albert Sakzewski Virus Research
Center, Royal Children's Hospital, (A. Falconar, 1991) describes
the search for the NS1 nonstructural glycoprotein in the serum of
patients-infected with the DEN2 virus. The authors of this report
have developed a double-sandwich ELISA assay in which a rabbit
serum containing polyclonal anti-NS1 antibodies, used as capture
antibodies, is immobilized on a microtitration plate. The antigen
captured is detected using mouse monoclonal antibodies directed
against the NS1 protein, either of the dengue virus of the DEN2
type, or specific for the serological complex of dengue; the
formation of the antigen/antibody complex is revealed using
peroxidase-conjugated goat anti-mouse IgG. With this method, the
authors have shown, by using the degraded or purified dimeric. NS1
protein as the standard, that the sensitivity of detection of the
assay is approximately 4 ng/ml with the DEN2 monoclonal antibodies
as the revelation probe and approximately 60 ng/ml with the group
monoclonal antibodies.
[0018] However, this assay does not make it possible to detect the
NS1 protein either in the case of primary infections in the acute
or convalescent phase, or in secondary infections in the
convalescent phase in which there is a high titer of anti-NS1
antibodies; the authors have concluded therefrom that the NS1
protein must be present in large amounts only in cases of secondary
infections, this being transiently, during the infection.
[0019] Now, the inventors have developed a method for purifying the
NS1 protein of a flavivirus, in the hexameric form, which has
allowed them to select antibodies specific for this protein in
hexameric form, and to show, surprisingly, that these antibodies
are tools of choice for demonstrating the various problems of the
circulating NS1 protein in the context of an infection with a
flavivirus, in particular in the early phases in which the specific
antibody response is undetectable, especially during primary
infections with the dengue virus.
[0020] Consequently, the inventors have given themselves the aim of
providing a method for the early detection of a flaviviral
infection, which corresponds to practical needs better than the
methods of the prior state of the art, i.e. a method which is
reliable, rapid and inexpensive and which makes it possible to
adapt the medical care in time.
[0021] Consequently, a subject of the present invention is a method
for the early detection of a flaviviral infection, characterized in
that it comprises detecting the NS1 nonstructural glycoprotein of a
flavivirus in a biological sample, throughout the duration of the
clinical phase of the infection, by an immunological method using
at least two antibodies, which may be identical or different,
[0022] the first antibody or antibody for capturing the NS1
glycoprotein consisting of antibodies chosen from the group
consisting of: [0023] polyclonal antibodies preselected by
immunocapture on the NS1 protein of said flavivirus, in the
hexameric form, and [0024] mixtures of anti-NS1 monoclonal
antibodies preselected for their high affinity for the NS1 protein
of said flavivirus, in the hexameric form, said monoclonal
antibodies then being purified, [0025] the second antibody or
revelation antibody being chosen from the group consisting of:
[0026] polyclonal antibodies directed against the NS1 protein in
the hexameric form, and [0027] a mixture of monoclonal antibodies
directed against the NS1 protein in the hexameric form.
[0028] For the purpose of the present invention, the expression
"hexameric form of the NS1 protein of a flavivirus" is intended to
mean the native protein obtained from the culture supernatant of
mammalian cells infected with said flavivirus or transformed using
an expression system comprising the gene of the NS1 protein of said
flavivirus, and purified according to the method of the invention
as described below. This hexameric form of said NS1 protein, which
differs from other forms such as the monomeric form or the dimeric
form of said protein, is demonstrated using electrophoresis or
chromatography techniques such as those described in FIG. 1.
[0029] For the purpose of the present invention, the expression
"polyclonal and monoclonal antibodies directed against the NS1
protein of a flavivirus" is intended to mean antibodies obtained by
immunizing a nonhuman mammal, [0030] either with an NS1 protein in
the hexameric form, [0031] or with a live or inactivated
flavivirus, said polyclonal antibodies being selected for their
affinity for the NS1 protein in the hexameric form and purified in
a single step, and said monoclonal antibodies being preselected for
their high affinity for the NS1 protein in the hexameric form and
then purified by conventional techniques, in particular by ion
exchange or affinity chromatography.
[0032] For the purpose of the present invention, the expression
"affinity of a monoclonal antibody for the NS1 protein in the
hexameric form" is intended to mean the concentration of said
protein required to saturate 50% of the sites of the antibody; this
is measured by the affinity constant of said antibody, according to
the protocol described in example 5.
[0033] For the purpose of the present invention, the term "high
affinity" is intended to mean an affinity for which the constant is
less than 10.sup.-8 M.
[0034] Surprisingly, the use, for detecting the NS1 protein in a
biological sample, of polyclonal antibodies selected and purified
by immunocapture on the NS1 protein in the hexameric form, or of
monoclonal antibodies which have a high affinity for the NS1
protein in the hexameric form and which are purified, instead of a
total hyperimmunized rabbit serum, makes it possible to
significantly improve the sensitivity of the method and to detect
the NS1 protein circulating in the blood of patients, from the
early stage of infection, both during a primary infection and a
secondary infection.
[0035] The method according to the present invention has a certain
number of advantages: [0036] it may be carried out early: the
presence of the NS1 glycoprotein is revealed during the clinical
phase, before the antibody response is detectable, [0037] it is
sensitive: it is possible to detect as little as less than 1 ng of
protein/ml of serum, which makes it possible to detect the
circulating NS1 protein in the early phase of primary infections,
[0038] it is rapid: an answer can be obtained within a day, [0039]
it is relatively inexpensive and can therefore be used in the
countries at risk, [0040] it makes it possible to distinguish
vaccinated individuals from individuals recently infected with a
flavivirus, since the NS1 protein will be absent in vaccinated
individuals in which the antibodies may still be detectable.
[0041] According to an advantageous embodiment of said method, the
flaviviral infection is an infection with the dengue virus.
[0042] According to another advantageous embodiment of said method,
the first antibody is preferably attached to a suitable solid
support and the second antibody is optionally conjugated to a
suitable label.
[0043] According to another advantageous embodiment of said method,
when the second antibody is not conjugated to a label, its binding
to the NS1 protein attached to the solid support is then detected
with a third antibody, conjugated to a suitable label, said third
antibody being a conventionally used antibody, such as for example
an IgG directed against the second antibody and produced in
particular in the goat, the pig or the donkey.
[0044] Among the labels used, mention may be made, by way of
example, of fluorescent labels, the biotin/streptavidin system,
nonisotopic labels or enzymes, such as for example horseradish
peroxidase or alkaline phosphatase.
[0045] According to another advantageous embodiment of said method,
said third antibody is conjugated to an enzyme.
[0046] According to another advantageous embodiment of said method,
[0047] the first antibody, or capture antibody, consists of mouse
polyclonal antibodies selected by immunocapture on the NS1 protein
of the dengue virus, said protein being in the hexameric form, and
[0048] the second antibody, or antibody for detecting the presence
of NS1 in the biological sample to be analyzed, consists of
polyclonal antibodies from a rabbit immunized with the NS1 protein
of the dengue virus, said protein being in the hexameric form, the
attachment of said second antibody being revealed with a third
antibody, consisting of antibodies conjugated to peroxidase and
directed against the second antibody.
[0049] According to another even more advantageous embodiment of
said method, the mouse polyclonal antibodies are purified by
immunocapture on the hexameric NS1 protein of dengue serotype
1.
[0050] A subject of the present invention is also a kit or boxed
set for diagnosing a flaviviral infection, characterized in that it
comprises: [0051] at least one capture antibody and at least one
revelation antibody as defined above, [0052] at least one positive
control consisting of the NS1 protein of a flavivirus and/or of
various serotypes depending, on the flavivirus, said protein being
in a hexameric form, and [0053] at least one negative control
consisting of a normal human serum.
[0054] According to an advantageous embodiment of the boxed set for
diagnosis according to the invention, said NS1 protein in the
hexameric form is obtained from a culture supernatant either from
infected mammalian cells or from mammalian cells transfected with a
recombined plasmid comprising the gene of the NS1 protein or a
fragment of said gene or a fragment of the flaviviral genome, said
fragments being capable of expressing all or part of the NS1
protein.
[0055] According to another advantageous embodiment of the boxed
set for diagnosis according to the invention, the NS1 protein is
that of the dengue virus.
[0056] According to an even more advantageous embodiment of said
boxed set for diagnosis, the plasmid is the pCIneo-NS1.FGA plasmid
which was deposited with the Collection Nationale de Cultures et de
Microorganismes [National collection of cultures and
microorganisms] held by the Institut Pasteur under the number
I-2220, dated Jun. 7, 1999.
[0057] A subject of the present invention is also a method for
purifying the NS1 protein of a flavivirus, in the hexameric form,
from a culture supernatant either of infected mammalian cells or of
mammalian cells transfected with a recombined plasmid comprising
the gene of the NS1 protein of a flavivirus or a fragment of said
gene or a fragment of the flaviviral genome, said fragments being
capable of expressing the NS1 protein in a hexameric form,
characterized in that, prior to the purification of the NS1 protein
using conventional techniques such as affinity chromatography, the
soluble form of the NS1 protein is separated from the
microparticulate form of said proteins by treatment with a
precipitating agent and then by centrifugation.
[0058] For example, the centrifugation is carried out at a speed
greater than or equal to 10 000 g.
[0059] For the purpose of the present invention, the term
"precipitating agent" is intended to mean an agent which
precipitates specifically microparticulate proteins or cellular
debris, such as for example polyethylene glycol, said agent being
used under conventional conditions which make it possible to
separate soluble proteins and microparticulate proteins or cellular
debris.
[0060] In a preferred embodiment of said purification method, the
hexameric NS1 protein is that of the dengue virus, in particular
dengue virus serotype 1.
[0061] A subject of the present invention is also an immunogenic
composition, characterized in that it comprises, as the active
principle, the NS1 protein of a flavivirus, in the hexameric form,
optionally associated with other proteins, in combination with at
least one pharmaceutically acceptable vehicle.
[0062] In a preferred embodiment of the immunogenic composition
according to the present invention, the immunogenic composition
comprises at least one mixture of the NS1 proteins in the hexameric
form corresponding to the various dengue virus serotypes.
[0063] A subject of the present invention is also an immunogenic
composition, characterized in that it comprises an active principle
selected from the group consisting of: [0064] a polynucleotide
capable of expressing all or part of the NS1 protein of the dengue
virus, whatever its serotype, [0065] an expression system
comprising at least one promoter capable of expressing, in the host
into which it is injected, a DNA encoding the NS1 protein of the
dengue virus, whatever its serotype, said DNA expressing said
protein, in combination with at least one pharmaceutically
acceptable vehicle.
[0066] Vaccination protocols using nucleic acids are described in
particular in international application WO 90/11092.
[0067] A subject of the present invention is the use of an NS1
protein of a flavivirus, in the hexameric form, or of a system for
the expression thereof, for preparing an immunogenic composition
capable of inducing the production of antibodies in vivo.
[0068] In a preferred method of said use, the NS1 protein is that
of the dengue virus, in particular dengue virus serotype 1.
[0069] A subject of the present invention is also the use of at
least one monoclonal anti-NS1 antibody having a high affinity for
the NS1 protein in the hexameric form, said monoclonal antibodies
then being purified, and modified, for manufacturing a medicinal
product capable of inducing passive immunization.
[0070] Advantageously, the modifications to the antibodies are, in
particular, the selection of Fab fragments or the humanization of
the antibodies.
[0071] A subject of the present invention is also the use of the
NS1 protein in the hexameric form, for selecting in vitro
antibodies specific for said NS1 protein, able to diagnose an
infection with a flavivirus, at an early stage.
[0072] In an advantageous embodiment of said use, the antibodies
are polyclonal antibodies.
[0073] In another advantageous embodiment of said use, the
antibodies are monoclonal antibodies.
[0074] In another advantageous embodiment of said use, the protein
is the NS1 protein of the dengue virus, in particular dengue virus
serotype 1.
[0075] The anti-NS1 monoclonal antibodies are advantageously
obtained by fusing spleen cells from a mouse immunized with the NS1
protein in the hexameric form, with suitable myeloma cells.
[0076] A subject of the present invention is also a method for
expressing a polynucleotide encoding the NS1 protein of a dengue
virus, characterized in that it comprises the expression of a
polynucleotide as defined in the sequence SEQ ID No. 1, associated
with a promoter for said polynucleotide, in suitable eukaryotic
cells.
[0077] Other characteristics and advantages of the invention appear
in the remainder of the description and the examples illustrated by
the figures in which:
[0078] FIG. 1 represents the purified hexameric extracellular NS1
protein obtained after exclusion chromatography. (a) After
exclusion chromatography, the protein is concentrated to 0.5 mg/ml
by ultrafiltration and treated with dimethyl suberimidate (DMS) at
0, 0.5, 5 and 50 mM. The products obtained are placed in a
nonreducing Laemmli buffer, separated on a 4 to 20% gradient
acrylamide gel and stained with Coomassie blue. A sample treated
with 50 mM DMS is heated for 3 min at 95.degree. C. before
electrophoresis in order to dissociate the noncovalent oligomers.
(b) The purified NS1 protein is treated overnight at 37.degree. C.
with 0.5% or 1% of n-octylglucoside (nOG) and, optionally, treated
with 25 mM of DMS for 1 hour. The proteins are separated without
heat denaturation on a 4 to 20% gradient acrylamide gel and
detected via immunoblotting with a monoclonal anti-NS1 antibody
from the literature or as defined above.
[0079] FIG. 2 represents the sequence of the NS1 protein of dengue
virus serotype 1, obtained with clone 4C of example 2 below, and
also the corresponding coding sequence.
[0080] FIG. 3 illustrates the results obtained by assaying the
circulating NS1 protein using the method of detection by
capture-ELISA in patients infected beforehand with a dengue virus,
whose sera were taken during the acute and convalescent phases, and
also the comparison with the results obtained using the techniques
of the prior art, IHA (inhibition of hemagglutination of dengue
virus serotypes 1, 2, 3 or 4) and MAC ELISA (immunoglobulin M
Antibody Capture Enzyme-Linked ImmunoSorbent Assay); D1 corresponds
to dengue serotype 1; D2 corresponds to dengue serotype 2; D3
corresponds to dengue serotype 3 and D4 corresponds to dengue
serotype 4; ID=patient's identity; 1 corresponds to the first
sample in the acute phase of the disease, 2 corresponds to the
second sample in the convalescent phase (taken 2 to 4 weeks after
the first); in the capture-ELISA assay, the values are expressed as
optical density obtained for the same serum diluted 10, 30 or 90
times.
[0081] FIG. 4 illustrates the detection of the NS1 protein using
the capture-ELISA assay on sera from patients infected with dengue
virus serotype 1 from French Guiana. The numbers indicated
represent the number of patients divided up per category
(positivity or negativity by capture-ELISA and positivity or
negativity for IgM).
[0082] FIG. 5 illustrates the results obtained for 4 patients from
French Guiana infected with dengue virus 1, from whom samples were
taken daily during the clinical phase of the disease from D1 to D5.
Each graph corresponds to a patient with, for each day on which a
sample was taken, both the results of detection of the NS1 protein
with the capture-ELISA assay developed., the results of RT-PCR and
the results obtained using the MAC-ELISA technique. The O.D. values
reported were corrected for once the value of the background noise.
The positivity thresholds are indicated by the broken lines.
[0083] FIG. 6 indicates the characteristics of the anti-NS1
monoclonal antibodies F22 and G18.
[0084] FIG. 7 illustrates the detection of the NS1 protein with the
capture-ELISA assay using the monoclonal approach in comparison
with the capture-ELISA assay using the polyclonal approach as
described in example 3. The results obtained are reported in the
form of optical density values measured for each dilution of serum
analyzed (10th, 30th or 90th) and less the mean value of the
negative controls.
[0085] FIG. 8 illustrates the demonstration of the NS1 protein in
the sera from patients infected with the yellow fever virus, using
an capture-ELISA assay specific for yellow fever. For each serum
tested, the optical density value measured using the assay
developed, less the mean value of the negative controls, the
optical density value measured using the MAC-ELISA assay specific
for yellow fever IgMs and the results of the viral isolation, when
they are available, are reported.
EXAMPLE 1
Purification of the NS1 Protein of Dengue Virus Serotype 1
1. Materials and Methods
[0086] The protein is produced on Vero cells infected with dengue
virus serotype 1, strain FGA/89 (P. Despres et al., Virol, (1993),
196, 209-219), under the conditions adapted for the method
described by A. K. I. Falconar et al., (J. Virol. Meth, (1990), 30,
323-332).
[0087] The culture medium is harvested 5 days after infection and
centrifuged at 1500 g to remove the cellular debris. The
centrifugation supernatant is brought to 20 mM Tris-HCl, 1 mM
sodium azide, and concentrated 6 times by cold ultrafiltration, and
the viral particles are removed by precipitation for 2 h at
4.degree. C., with a concentration of 7.5% of polyethylene glycol
(PEG), followed by centrifugation for 30 minutes at 10 000 g. The
clarified supernatant, containing 7.5% PEG is treated with 0.05%
Tween 20 and 1 mg/ml of aprotinin, and then passed over an
immunoaffinity column to which is attached an anti-NS1 monoclonal
antibody. The protein is eluted according to the diethylamine
technique, as described in Falconar et al., (mentioned above), and
concentrated by ultrafiltration, and the elution solution is
exchanged with a 10 mM Tris-HCl buffer, pH 7.5, containing 1 mM of
sodium azide.
2. Results
[0088] The results are illustrated in FIG. 1.
[0089] FIG. 1a shows that the NS1 protein is indeed in the
hexameric form. The proportion of hexameric form increases with an
increase in concentration of DMS (FIG. 1a).
[0090] The extracellular NS1 protein in the hexameric form may be
transformed into dimeric subunits in the presence of the nonionic
detergent n-octylglucoside (nOG) (FIG. 1b). After incubation
overnight at 37.degree. C. in the presence or absence of
n-octylglucoside (nOG) and treatment with 25 mM DMS, it is observed
that, in the absence of nOG, bands are present which correspond to
the dimer, to the tetramer and to the hexamer, and that, in the
presence of nOG, there is partial or complete dissociation of the
hexamer depending on the concentration of nOG (FIG. 1b).
EXAMPLE 2
Expression of the NS1 protein of Dengues Virus Serotype 1 by Vero
Cells
[0091] 1. Materials and methods
[0092] The pCIneo-NS1.FGA plasmid (deposited with the Collection
Nationale de Cultures et de Microorganismes [National collection of
cultures and microorganisms] (CNCM) of the Institut Pasteur under
the No. I-2220, dated Jun. 7, 1999) containing the gene of the NS1
protein comprising the gene encoding its signal peptide, preceded
by a translation initiation codon and followed by a translation
termination codon, is introduced into the competent bacterium
Escherichia coli (epicurian SURE from Stratagene). This plasmid is
amplified in bacterial culture and purified according to the
conventional technique for preparing plasmid DNA. The purified DNA
is used to sequence various clones (the sequence of clone 4C is
illustrated in FIG. 2) and to transfect Vero cells using either a
suitable mixture with cationic liposomes, such as DOTAP (Boehringer
Mannheim), or with a nonliposomal agent, such as FuGENE (Boehringer
Mannheim). The FuGENE and the DNA are pre-incubated in medium
without serum for 15 min, and then the mixture is brought into
contact with a layer of Vero cells for 24 h. The cells are then
rinsed with PBS (phosphate buffered saline), fixed for 20 min at
room temperature with a solution of PBS containing 3% of
paraformaldehyde and permeabilized for 5 min with PBS containing
0.5% Triton X-100. The presence of NS1 antigen is then revealed
using specific antibodies, which are recognized by a
fluoroscein-labeled conjugated antibody.
2. Results
[0093] It is thus possible to demonstrate a strong fluorescent
signal, specific for the NS1 viral antigen, in approximately 20% of
the transfected cells.
[0094] The expression of NS1 is thus demonstrated and stable lines
may be established in the presence of neomycin, which is a
selection marker for the transfected cells.
[0095] FIG. 2 illustrates the sequence of the NS1 protein of dengue
virus serotype 1 thus obtained, and also the corresponding coding
sequence.
EXAMPLE 3
Implementation of the Capture-ELISA Technique According to the
Invention in the Context of an Infection with Dengue Virus Serotype
1 and Comparison with the Methods of the Prior State of the Art
1. Principle of the Capture-ELISA Technique
[0096] The NS1 viral antigen is captured using monospecific mouse
polyclonal antibodies purified beforehand by immunocapture on the
purified hexameric NS1 protein of dengue serotype 1.
[0097] The presence of NS1 is revealed using antibodies from
rabbits immunized with the purified hexameric NS1 protein,
themselves recognized by antibodies conjugated to horseradish
peroxidase.
2. Materials and methods a--Purification of Mouse Polyclonal
Antibodies Directed Against the NS1 Protein a.sub.1--Attachment of
the NS1 Protein to a Membrane
[0098] The purified NS1 protein is attached by adsorption to an
amphoteric nylon membrane (Nytran, Schleicher & Schuell). The
surface of the membrane is then saturated with bovine albumin
present at a concentrate of 3% in a phosphate buffered saline
solution (PBS; 10 mM phosphate; pH 7.2; 150 mM NaCl). After 2
rinses in PBS, the membrane is treated with PBS containing 0.25% of
glutaraldehyde for 15 min at room temperature. After 3 rinses in
PBS, the membrane is neutralized with a 100 mM glycine buffer
containing 3% bovine albumin, rinsed twice in PBS and then stored
at 4.degree. C. in PBS with 1 mM sodium azide.
a.sub.2--Purification of the Mouse Monospecific Polyclonal
Antibodies (Capture Antibodies) [0099] production of polyclonal
ascites: the brains of young Swiss mice infected with dengue virus
and moribund are ground in 9 ml of PBS buffer. The product is
centrifuged for 10 min at 10 000 g at 4.degree. C.
[0100] The viral suspension is injected into Swiss mice, according
to the following calendar of events: [0101] D0: 0.5 ml of antigen
subcutaneously into the thigh, [0102] D3: 0.4 ml of antigen and 0.1
ml of complete Freund's adjuvant intraperitoneally, [0103] D25: 0.5
ml of antigen intraperitoneally, [0104] D26: 0.5 ml of TG180 mouse
ascites, and [0105] D28: 0.5 ml of antigen intraperitoneally.
[0106] The ascites are harvested on D42.
[0107] After having collected the ascites, the coagulum is allowed
to form for 1 hour at room temperature and then centrifugation is
carried out for at least 30 min at 1500 g. The supernatant is left
to stand overnight at 4.degree. C. The pH of the supernatant is
adjusted to 4.8 with 2M acetic acid and the supernatant is then
centrifuged again under the same conditions. The pH of the
supernatant is then brought to 7.0-7.2 by adding a 2N sodium
hydroxide solution. The supernatant may be stored at -20.degree.
C.
[0108] Purification of the Mouse Antibodies Specific for Dengue
Virus Serotype 1:
[0109] The membrane is incubated for one hour at room temperature
in a mixture of polyclonal ascites directed against the 4 dengue
virus serotypes prepared as described above.
[0110] After rinsing the membrane 3 times in PBS, the antibodies
attached to the NS1 protein are eluted with a diethylamine
solution, pH 11.4 (Dubelco medium modified with Iscove (Gibco)
containing 100 mM diethylamine). The antibodies are concentrated by
ultrafiltration and returned to a PBS buffer containing 1 mM sodium
azide.
b--Preparation of Rabbit Polyclonal Antibodies Directed Against the
NS1 Protein (Revelation Antibodies):
[0111] The rabbits were immunized with 3 or 4 successive injections
of 30 .mu.g of hexameric NS1 protein purified according to the
method of example, 1, given on D0, D7, D21 and, optionally, on D49,
and followed by bleeding out on D83. The serum is depleted of
nonspecific signal by incubation with Sepharose beads bearing a
monoclonal antibody described in the literature or prepared as
described above.
c--Capture-ELISA Method c.sub.1--Standard Curve
[0112] For each capture-ELISA plate intended for testing human
sera, a standard range is prepared from a solution of NS1 protein
purified according to the method described in point 1, the initial
concentration of which is 0.5 .mu.g/ml, and which is diluted in
3-fold serial dilutions.
C.sub.2--Detection of the Circulating NS1 Protein During the Acute
Phase:
[0113] The purified mouse polyclonal antibodies obtained according
to the method described above (capture antibodies) are attached to
a plate, diluted in a PBS solution and left to incubate overnight
at 4.degree. C. After 3 rinses for 5 minutes with a solution of
PBS/0.05% Tween, the plate is saturated with a mixture of PBS,
0.05% Tween and 3% milk for 30 minutes at room temperature. After 3
rinses with a solution of PBS/0.05% Tween, the sera to be tested,
diluted or undiluted, are deposited and left to react for one hour,
still at room temperature. The 1/10th, 1/30th and 1/90th dilutions
are prepared in a solution of PBS/0.05% Tween. After 3 rinses, the
second antibody specific for NS1 (revelation antibody obtained in
point 3 above) is added, after having been diluted in a mixture of
PBS/0.05% Tween and of 3% milk, and left to incubate for 45 minutes
at 37.degree. C. After 3 rinses, the anti-agG antibodies are
directed against the second antibody and labeled with peroxidase,
said antibody being prepared under conventional conditions known to
those skilled in the art, is added and the incubation is carried
out for 45 minutes at 37.degree. C. After 3 rinses, revelation is
carried out for 10 minutes with a solution of TMB
(3,3',5,5'-tetramethylbenzidine, Kierkegaard & Perry Lab). The
calorimetric reaction is stopped with sulfuric acid.
3. Results
[0114] They are illustrated in FIG. 3.
[0115] The capture-ELISA technique according to the invention makes
it possible to detect the presence of NS1 protein in the acute
phase of the disease, this detection being independent of whether
the patients have a primary or secondary infection.
[0116] The results confirm that the presence of the NS1 protein is
transient, since this protein is not detected in the samples taken
in the convalescent phase (FIG. 3).
[0117] 93% of the samples taken in the acute phase of the disease
prove to be negative using the MAC ELISA assay, whereas 100% of the
samples taken in the convalescent phase prove to be positive in
this same assay (FIG. 3).
[0118] Similarly, the inhibition of hemagglutination assay (IHA)
does not make it possible to detect infection with dengue virus
serotype 1 in 80% of cases in the acute phase of the disease, but
this test proves to be positive in 100% of the samples taken in the
convalescent phase (FIG. 3). According to the WHO criteria, an IHA
level of less than 1280 in the serum taken in the convalescent
phase allows diagnosis of a primary dengue infection and a level of
greater than 1280 allows diagnosis of a secondary dengue
infection.
[0119] Half of the positive sera in this study therefore correspond
to cases of primary dengue and the other half to cases of secondary
dengue. The capture-ELISA technique according to the invention thus
makes it possible to detect the NS1 protein in cases of primary and
secondary dengue.
EXAMPLE 4
Determination of the Detection Window
1. Materials and Methods
[0120] a--Study Carried Out on a Population of Patients from French
Guiana Infected With Dengue Virus 1
[0121] The samples are taken from patients infected with dengue
virus serotype 1, between D0, marking the appearance of the
clinical signs (initially a nondifferentiated fever) and D66
corresponding to the end of the convalescent phase.
[0122] The presence of circulating NS1 is sought in the sera of
these patients, according to the capture-ELISA method described in
example 3, and the result obtained is compared with the positivity
for specific IgMs measured by MAC-ELISA, when the data are
available.
b--Daily Monitoring of 4 Patients Infected with Dengue Virus 1
[0123] Samples were taken daily from 4 patients during the clinical
phase from D1 to D5. An RT-PCR reaction to reveal the viral RNA, a
MAC-ELISA assay to detect IgMs specific for dengue virus and a
search for the dengue NS1 antigen according to the capture-ELISA
method described above were carried out on each blood sample.
2. Results
[0124] a--Determination of the Detection Window
[0125] The results are given in FIG. 4.
[0126] Between D1 and D6, the Possibility of detecting the
circulating NS1 protein oscillates between 64% (on D2) and 100% (on
D5) of the infected patients. Beyond D10, the circulating NS1
protein is no longer detected, whereas the antibody response
becomes predominant.
[0127] Detection of the circulating NS1 protein does not appear to
be dependent on the presence of total Igms (specific for the viral
antigens) which appear, in certain cases, on D3 and culminate from
D5, nor even, for certain patients, on the presence of total IgGs
which may appear from D2. On the other hand, the absence of
detection of the NS1 antigen in clinical phase sera may be
explained by the presence of IgGs specifically directed against
NS1.
[0128] Thus, the detection window for the NS1 antigen in the serum,
using the capture-ELISA technique according to the present
invention, is preferably between D1 and D6 after appearance of the
clinical signs.
b--Daily Monitoring of 4 Patients Infected with Dengue Virus
[0129] The results are given in FIG. 5.
[0130] In the 4 patients studied, the NS1 protein is detected
continuously up to D5, this being regardless of the day on which
the sample was taken relative to the start of symptoms. For certain
patients, the detection window for the protein is wider than the
period of viremia, detected by RT-PCR.
EXAMPLE 5
Implementation of the Capture-ELISA Technique with Monoclonal Tools
in the Context of an Infection with Dengue Virus Serotype 1 and
Comparison with the Capture-ELISA Technique Described Above
1. Materials and Methods
[0131] a--Production and Characterization of Mouse Monoclonal
Antibodies Directed Against the NS1 Protein of Dengue Virus
Serotype 1 a.sub.1--Production Of Mouse Monoclonal Antibodies
Directed Against the NS1 Protein
[0132] Female Balb/C mice were immunized with 7 injections of 10
.mu.g of hexameric NS1 protein of dengue virus serotype 1, purified
according to the method of example 1. The first injection in
complete Freund's adjuvant and the subsequent five injections in
incomplete Freund's adjuvant are given subcutaneously 15 days
apart. The final injection, in incomplete Freund's adjuvant, given
three days before the animal is sacrificed, is given
intraperitoneally.
[0133] The cells from the spleen of the immunized mice are fused
with the murin myeloma and cultured until clones appear, according
to standard protocol.
a.sub.2--Identification of Hybridomas Secreting Anti-Ns1
Antibodies
[0134] Antibodies specific for the NS1 protein were detected either
using a conventional ELISA technique or using a capture-ELISA
technique.
--Conventional ELISA Technique
[0135] The hexameric NS1 protein purified according to the method
of example 1 is attached to a plate by adsorption, at the
concentration of 1 .mu.g/ml in a PBS solution overnight at
4.degree. C. After 3 washes with a solution of PBS/0.1% Tween (PT),
the protein is incubated with the supernatants of the various
hybridomas diluted two-fold with a solution of PT containing 0.5%
gelatin (PTG), for 1 h at 37.degree. C. After 3 washes with PT, the
peroxidase-labeled anti-mouse IgG antibody diluted in PTG is added
and incubated for 1 h at 37.degree. C. After 3 washes, revelation
is carried out with a solution of hydrogen peroxide in the presence
of orthophenylenediamine.
[0136] --Capture-ELISA Technique
[0137] The technique used is described in example 3 (cf. detection
of the circulating --NS1 protein in the acute phase)., but
replacing the dilutions of sera to be tested with a 1/10th
dilution, in the PTG solution, of culture supernatant on uninfected
Vero cells or Vero cells infected for 5 days with dengue virus
serotype 1, and precipitated with 7% of polyethylene glycol (cf.
example 1: purification of the NS1 protein of dengue virus serotype
1). The reactivity of the supernatants from the various hybridomas
with respect to the culture supernatant from uninfected Vero cells
is used as a control for nonspecific signal.
a.sub.3--Reactivity of the Anti-NS1 Monoclonal Antibodies, by
Indirect Immunofluorescence, on Vero Cells Infected with One of the
4 Dengue Virus Serotypes
[0138] The Vero cells are infected for 40 h with one of the 4
dengue virus serotypes: [0139] serotype 1: strain FGA/89 [0140]
serotype 2: strain NG [0141] serotype 3: strain H87 [0142] serotype
4: strain H241
[0143] After 1 wash with a solution of PBS, the cells are fixed
with a solution of 3% paraformaldehyde in PBS for 30 minutes at
laboratory temperature. The cells rinsed in PBS are then
permeabilized with a solution of 0.5% Triton X-100 in PBS for 10
minutes. After rinsing in PBS, the cells are incubated for 1 h with
the supernatants from the various hybridomas which have reacted
positively by ELISA. After 3 washes with PBS, the
fluorescene-labeled anti-mouse IgG antibody is added and incubated
for 1 h. After 3 washes in PBS, the slides are covered with a
coverslip and observed under a fluorescent microscope.
a.sub.4--Preparation of the Mouse Monoclonal Ascites
[0144] The monoclonal ascites are produced in Balb/C mice. The mice
are given an intraperitoneal injection of 0.5 ml of pristane
(2,6,10,14-tetramethylpentadecane, Sigma) one week before the
intraperitoneal injection of the hybridoma clone secreting the
monoclonal antibody. The ascites are removed as they form,
centrifuged at 1500 rpm for 20 minutes and stored at -20.degree.
C.
a.sub.5--Determination of the Isotype of the Anti-NS1 Monoclonal
Antibodies
[0145] The isotype of the anti-NS1 antibody is determined by ELISA
using antibodies directed against the various murine immunoglobulin
subclasses: IgG1, IgG2a, IgG2b and IgG3. The light chain of the
immunoglobulin is determined according to an identical
methodology.
a.sub.6--Determination of the Affinity Constant of the Anti-NS1
Monoclonal Antibodies (B Friguet et al., J. Immunol, (1985), 77,
305-319)
[0146] The affinity of an antibody corresponds to the concentration
of antigen required to saturate 50% of the sites of the antibodies.
An incubation is carried out in liquid medium between the antibody
at constant concentration and the antigen at decreasing
concentration overnight at 4.degree. C. in order to reach the
equilibrium of the reaction. The concentration of free antibodies,
after equilibrium, is determined using an ELISA assay: the mixture
is deposited onto a plate preincubated with the antigen. After
incubation for 20 minutes at 4.degree. C. (to avoid a shift of the
equilibrium), the ELISA is revealed with a P-galactosidase-coupled
anti-mouse IgG, followed by the enzymatic reaction. The
dissociation constant KD is then determined.
a.sub.7--Competition Reaction for the Various Anti-NS1 Monoclonal
Antibodies
[0147] This reaction makes it possible to determine the specificity
of the monoclonal antibodies with respect to the same epitope or to
different epitopes. Epitope determination brings into play the
reactivity for an antigen, of an unlabeled monoclonal antibody and
of a second monoclonal antibody, coupled to biotin.
[0148] The first monoclonal antibody, unlabeled, is placed at
saturating concentration (determined beforehand by ELISA) on a
plate to which the antigen has been attached beforehand, and
incubated for 2 h at 37.degree. C. After 4 washes in PT solution at
4.degree. C., the second monoclonal antibody, coupled to biotin, is
added and incubated for 20 minutes at 4.degree. C. After 4 washes
in PT solution at 4.degree. C., the solution of peroxidase-labeled
streptavidin conjugate is added and incubated for 1 h at 37.degree.
C. After 4 washes in PT solution, the complex is revealed with a
solution of hydrogen peroxide in the presence of
orthophenylenediamine. If a signal is obtained after reading on a
spectrophotometer, this indicates that the epitopes recognized by
the 2 antibodies are different. If the opposite is true, the 2
monoclonal antibodies are directed against the same epitope of the
antigen.
b--Purification of the Monoclonal Antibodies G18 and F22
[0149] The antibodies G18 and F22 are purified by immunoaffinity as
described in Exmaple 3.
c--Detection of the Circulating NS1 Protein, with a Capture-ELISA
Assay Using the Monoclonal Antibodies
[0150] The purified monoclonal antibodies G18 and F22 are mixed in
a solution of PBS at a given dilution and incubated overnight at
4.degree. C. The subsequent steps of this ELISA assay are similar
to those of the previous example.
d--Comparison of the Capture-ELISA Assay Using the Monoclonal
Approach with that Using the Polyclonal Approach
[0151] A panel of serum from French Guiana was tested on the same
day with the capture-ELISA assay using the monoclonal approach and
then using the polyclonal approach. The sera are tested at various
dilutions: 10th, 30th and 90th.
2. Results
[0152] a--Characteristics of the Monoclonal Antibodies
[0153] The results are given in FIG. 6.
[0154] The antibodies G18 and F22 were selected for their ability
to bind, with high affinity, to different epitopes of the NS1
protein. The antibody F22 is specific for dengue virus serotype 1,
and G18 is specific for dengue virus serotypes 1 and 3.
b--Use of the Monoclonal Antibodies for NS1 Antigen Capture
[0155] The results are given in FIG. 7.
[0156] The monoclonal antibodies selected not only reproduce the
results obtained with the polyclonal approach, but they exhibit
more marked reactivities than the polyclonal antibodies. The
monoclonal tool developed therefore appears to be particularly
suitable for the diagnostic use which must be made of it.
EXAMPLE 6
Implementation of the Capture-ELISA Technique According to the
Invention in the Context of an Infection with Another Dengue Virus
Serotype or Another Flavivirus
[0157] 1. Materials and methods a--Preparation of Culture
Supernatants
[0158] The Vero cells are infected either with dengue virus, 2 or
with the Japanese encephalitis virus or the yellow fever virus. The
culture supernatants are then prepared according to the method
described in example 1.
b--Purification of the Monoclonal Antibodies Directed against the
NS1 Protein of the Yellow Fever Virus and of the Japanese
Encephalitis Virus
[0159] The monoclonal ascites of the antibodies 8G4, 1A5 and 2D10
(J. J. Schlesinger et al., Virology, (1983), 125, 8-17) directed
against the NS1 protein of the yellow fever virus, and of the
antibodies 171-2-2 and 70-14-20 directed against the NS1 protein of
the Japanese encephalitis virus, are purified on protein A
Sepharose CL-4B beads (Pharmacia Biotech). These monoclonal ascites
are incubated overnight at 4.degree. C. on the protein A beads.
After the beads have been rinsed 3 times in PBS/0.05% Tween, the
antibodies attached to the protein A beads are eluted with a
solution of glycine buffer, pH=3. They are then concentrated by
ultrafiltration and returned to a PBS buffer containing 1 mM sodium
azide.
c--Detection of the NS1 Protein in the Dengue Virus 2 Culture
Supernatants c.sub.1--Antibodies Used
[0160] The capture step is carried out with a mixture of ascites of
the monoclonal antibodies 3D1.4 and 1A12 (A. K. I. Falconar et al.,
Arch. Virology, (1994), 137, 315-326). The protein is then
recognized with a mixture of two rabbit antibodies: the serum
obtained after immunization with the purified protein described in
example 3 and a rabbit serum obtained after immunization with the
viruses of the four dengue serotypes.
c.sub.2--Capture-ELISA Method
[0161] The technique used is the same as that described in example
3.
d--Detection of the NS1 Protein in the Japanese Encephalitis Virus
Culture Supernatants d.sub.1--Antibodies Used
[0162] The purified monoclonal antibodies 171-2-2 and 70-14-20 are
used for the capture step. The protein is then recognized with a
mixture of two sera from rabbits which have been immunized
beforehand with recombined proteins of the NS1 protein of Japanese
encephalitis.
d.sub.2-Capture-ELISA Method
[0163] The technique used is the same as that described in example
3.
e--Detection of the NS1 Protein in the Yellow Fever Virus Culture
Supernatants and the Sera from Patients Infected with this Virus
e.sub.1--Antibodies Used
[0164] The purified monoclonal antibodies 8G4, 1A5 and 2D10 are
mixed, at a given dilution, in a solution of PBS and used as
capture antibodies. The second antibody specific for yellow fever
NS1 used originates from a serum of a rabbit immunized beforehand
against the NS1 protein of the yellow fever 17D virus (J. J.
Schlesinger et al., J. Immunol. (1985), 135, 2805-2809).
e.sub.2--Capture-ELISA Method
[0165] The technique used is the same as that described in example
3.
2. Results
[0166] Secretion of the NS1 protein has previously been reported in
in vitro cell cultures infected with various flaviviruses, the DEN2
virus (Winkler et al., Virology (1988), 162, 187-196, Pryor et al.,
Virology (1993) 194, 769-780), the tick-borne encephalitis virus
(Lee et al., J. Gen. Virol. (1989), 70, 335-343, Crooks et al., J.
Chrom. (1990), 502, 59-68, Crooks et al., J. Gen. Virol. (1994),
75, 3453-3460), the Japanese encephalitis virus (Mason, Virology
(1989), 169, 354-364, Fan et. al., Virology (1990), 177, 470-476),
the Murray valley encephalitis virus (Hall et al., J. Virol. Meth.
(1991), 32, 11-20) and the yellow fever virus (Post et al., Vir.
Res. (1990), 18, 291-302). As these results were obtained using
different ELISA techniques, we sought to demonstrate the protein,
using the capture-ELISA technique of the present invention, in
supernatants of infected mammalian cells.
[0167] The NS1 protein is detectable in the culture supernatants of
the Vero cells infected either with the DEN2 virus, with the
Japanese encephalitis virus or with the yellow fever virus.
[0168] It was also possible to demonstrate the protein, using this
technique, in sera from patients infected with the yellow fever
virus, as demonstrated by the results given in FIG. 8. Among the 18
sera generously provided by Ch. Mathiot (Institut Pasteur of
Dakar), 7 are positive by NS1 antigenemia, and, as for the DEN1
virus, detection of the circulating NS1 protein appears to be
indifferent to the presence of IgMs specific for yellow fever.
[0169] The capture-ELISA technique according to the present
invention makes it possible to detect the NS1 protein in the
culture supernatants of cells infected with various flaviviruses
and in the sera from patients infected with the yellow fever virus.
Because of this, it may have a diagnostic application for detecting
an infection with a flavivirus other than the DEN1 virus.
Sequence CWU 1
1
211137DNADengue virus type 1CDS(1)..(1134) 1atg agg agc gcg tcg ctt
tcg atg acg tgc att gca gtt ggc atg gtt 48Met Arg Ser Ala Ser Leu
Ser Met Thr Cys Ile Ala Val Gly Met Val1 5 10 15aca ctg tac cta gga
gtc atg gtt caa gcg gac tcg gga tgt gta atc 96Thr Leu Tyr Leu Gly
Val Met Val Gln Ala Asp Ser Gly Cys Val Ile20 25 30aac tgg aag ggc
aga gaa ctc aaa tgt gga agt ggc att ttt gtc act 144Asn Trp Lys Gly
Arg Glu Leu Lys Cys Gly Ser Gly Ile Phe Val Thr35 40 45aat gaa gtc
cac act tgg aca gag caa tac aaa ttc cag gct gac tcc 192Asn Glu Val
His Thr Trp Thr Glu Gln Tyr Lys Phe Gln Ala Asp Ser50 55 60cca aaa
aga ctg tca gca gcc att ggg aag gca tgg gag gag ggc gtg 240Pro Lys
Arg Leu Ser Ala Ala Ile Gly Lys Ala Trp Glu Glu Gly Val65 70 75
80tgt gga att cga tca gcc acg cgt ctt gag aac atc atg tgg aag caa
288Cys Gly Ile Arg Ser Ala Thr Arg Leu Glu Asn Ile Met Trp Lys
Gln85 90 95ata tca aat gaa ttg aac cac att cta ctt gaa aat gac atg
aaa ttc 336Ile Ser Asn Glu Leu Asn His Ile Leu Leu Glu Asn Asp Met
Lys Phe100 105 110aca gtg gtt gta gga gat gct aat gga att ttg gcc
cag ggg aaa aaa 384Thr Val Val Val Gly Asp Ala Asn Gly Ile Leu Ala
Gln Gly Lys Lys115 120 125atg atc agg cca caa ccc atg gaa cac aaa
tac tca tgg aaa agc tgg 432Met Ile Arg Pro Gln Pro Met Glu His Lys
Tyr Ser Trp Lys Ser Trp130 135 140gga aaa gcc aag atc ata gga gca
gac aca cag aat acc acc ttc atc 480Gly Lys Ala Lys Ile Ile Gly Ala
Asp Thr Gln Asn Thr Thr Phe Ile145 150 155 160atc gac ggc cca gac
act cca gaa tgc ccc gat gac caa aga gcg tgg 528Ile Asp Gly Pro Asp
Thr Pro Glu Cys Pro Asp Asp Gln Arg Ala Trp165 170 175aac att tgg
gaa gtt gag gac tat ggg ttt gga att ttc acg aca aac 576Asn Ile Trp
Glu Val Glu Asp Tyr Gly Phe Gly Ile Phe Thr Thr Asn180 185 190ata
tgg ctg aaa ttg cgt gac tcc tac acc caa atg tgt gac cac cgg 624Ile
Trp Leu Lys Leu Arg Asp Ser Tyr Thr Gln Met Cys Asp His Arg195 200
205cta atg tca gct gcc gtc aag gac agc aag gca gtc cat gct gac atg
672Leu Met Ser Ala Ala Val Lys Asp Ser Lys Ala Val His Ala Asp
Met210 215 220ggg tac tgg ata gaa agt gaa aag aac gag acc tgg aag
cta gcg aga 720Gly Tyr Trp Ile Glu Ser Glu Lys Asn Glu Thr Trp Lys
Leu Ala Arg225 230 235 240gcc tcc ttc ata gaa gtc aag aca tgc att
tgg ccg aaa tcc cac act 768Ala Ser Phe Ile Glu Val Lys Thr Cys Ile
Trp Pro Lys Ser His Thr245 250 255cta tgg agt aat gga gtt ttg gaa
agt gaa atg ata atc cca aag ata 816Leu Trp Ser Asn Gly Val Leu Glu
Ser Glu Met Ile Ile Pro Lys Ile260 265 270tat gga gga cca ata tct
cag cac aat tac aga cca ggg tat ttc aca 864Tyr Gly Gly Pro Ile Ser
Gln His Asn Tyr Arg Pro Gly Tyr Phe Thr275 280 285caa aca gca ggg
cca tgg cac cta ggt aag ttg gaa ttg gat ttt gac 912Gln Thr Ala Gly
Pro Trp His Leu Gly Lys Leu Glu Leu Asp Phe Asp290 295 300ttg tgt
gaa ggc acc aca gtt gtt gtg gat gaa cat tgt gga aat cga 960Leu Cys
Glu Gly Thr Thr Val Val Val Asp Glu His Cys Gly Asn Arg305 310 315
320ggt cca tct ctc aga act aca aca gtc aca gga aag ata atc cat gaa
1008Gly Pro Ser Leu Arg Thr Thr Thr Val Thr Gly Lys Ile Ile His
Glu325 330 335tgg tgt tgc aga tcc tgc acg tta ccc ccc tta cgc ttc
aga gga gaa 1056Trp Cys Cys Arg Ser Cys Thr Leu Pro Pro Leu Arg Phe
Arg Gly Glu340 345 350gac gga tgt tgg tat ggc atg gaa atc aga cca
gtt aag gag aag gag 1104Asp Gly Cys Trp Tyr Gly Met Glu Ile Arg Pro
Val Lys Glu Lys Glu355 360 365gag aac cta gtt agg tca atg gtc tct
gca taa 1137Glu Asn Leu Val Arg Ser Met Val Ser Ala370
3752378PRTDengue virus type 1 2Met Arg Ser Ala Ser Leu Ser Met Thr
Cys Ile Ala Val Gly Met Val1 5 10 15Thr Leu Tyr Leu Gly Val Met Val
Gln Ala Asp Ser Gly Cys Val Ile20 25 30Asn Trp Lys Gly Arg Glu Leu
Lys Cys Gly Ser Gly Ile Phe Val Thr35 40 45Asn Glu Val His Thr Trp
Thr Glu Gln Tyr Lys Phe Gln Ala Asp Ser50 55 60Pro Lys Arg Leu Ser
Ala Ala Ile Gly Lys Ala Trp Glu Glu Gly Val65 70 75 80Cys Gly Ile
Arg Ser Ala Thr Arg Leu Glu Asn Ile Met Trp Lys Gln85 90 95Ile Ser
Asn Glu Leu Asn His Ile Leu Leu Glu Asn Asp Met Lys Phe100 105
110Thr Val Val Val Gly Asp Ala Asn Gly Ile Leu Ala Gln Gly Lys
Lys115 120 125Met Ile Arg Pro Gln Pro Met Glu His Lys Tyr Ser Trp
Lys Ser Trp130 135 140Gly Lys Ala Lys Ile Ile Gly Ala Asp Thr Gln
Asn Thr Thr Phe Ile145 150 155 160Ile Asp Gly Pro Asp Thr Pro Glu
Cys Pro Asp Asp Gln Arg Ala Trp165 170 175Asn Ile Trp Glu Val Glu
Asp Tyr Gly Phe Gly Ile Phe Thr Thr Asn180 185 190Ile Trp Leu Lys
Leu Arg Asp Ser Tyr Thr Gln Met Cys Asp His Arg195 200 205Leu Met
Ser Ala Ala Val Lys Asp Ser Lys Ala Val His Ala Asp Met210 215
220Gly Tyr Trp Ile Glu Ser Glu Lys Asn Glu Thr Trp Lys Leu Ala
Arg225 230 235 240Ala Ser Phe Ile Glu Val Lys Thr Cys Ile Trp Pro
Lys Ser His Thr245 250 255Leu Trp Ser Asn Gly Val Leu Glu Ser Glu
Met Ile Ile Pro Lys Ile260 265 270Tyr Gly Gly Pro Ile Ser Gln His
Asn Tyr Arg Pro Gly Tyr Phe Thr275 280 285Gln Thr Ala Gly Pro Trp
His Leu Gly Lys Leu Glu Leu Asp Phe Asp290 295 300Leu Cys Glu Gly
Thr Thr Val Val Val Asp Glu His Cys Gly Asn Arg305 310 315 320Gly
Pro Ser Leu Arg Thr Thr Thr Val Thr Gly Lys Ile Ile His Glu325 330
335Trp Cys Cys Arg Ser Cys Thr Leu Pro Pro Leu Arg Phe Arg Gly
Glu340 345 350Asp Gly Cys Trp Tyr Gly Met Glu Ile Arg Pro Val Lys
Glu Lys Glu355 360 365Glu Asn Leu Val Arg Ser Met Val Ser Ala370
375
* * * * *